View in EDS HTML Full Text PDF Full Text

Authors' Reply to Pande et al. Comment on "Extended-Release Viloxazine Compared to Atomoxetine for Attention Deficit Hyperactivity Disorder".

Saved in:
Bibliographic Details
Title: Authors' Reply to Pande et al. Comment on "Extended-Release Viloxazine Compared to Atomoxetine for Attention Deficit Hyperactivity Disorder".
Authors: Price, Maxwell Z. (AUTHOR), Price, Richard L. (AUTHOR)
Source: CNS Drugs. Oct2023, Vol. 37 Issue 10, p939-940. 2p.
Subjects: Attention-deficit hyperactivity disorder, Atomoxetine, Benzodiazepines, Caffeine
Abstract: We recognize that a paradigm shift of this magnitude takes time, as psychostimulants have been the mainstay of pharmacologic ADHD treatment for generations, but we are grateful to the editor for giving us this forum to share the experiences of our patients and their families from which we can learn. Comment on "Extended-Release Viloxazine Compared to Atomoxetine for Attention Deficit Hyperactivity Disorder" Following the 5-day washout period of atomoxetine, post-treatment scores were compared with baseline pretreatment scores to confirm that baseline scores were re-established prior to initiating viloxazine extended release (VER). [Extracted from the article]
Copyright of CNS Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 172948642
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Authors' Reply to Pande et al. Comment on "Extended-Release Viloxazine Compared to Atomoxetine for Attention Deficit Hyperactivity Disorder".
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Price%2C+Maxwell+Z%2E%22">Price, Maxwell Z.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Price%2C+Richard+L%2E%22">Price, Richard L.</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22CNS+Drugs%22">CNS Drugs</searchLink>. Oct2023, Vol. 37 Issue 10, p939-940. 2p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Attention-deficit+hyperactivity+disorder%22">Attention-deficit hyperactivity disorder</searchLink><br /><searchLink fieldCode="DE" term="%22Atomoxetine%22">Atomoxetine</searchLink><br /><searchLink fieldCode="DE" term="%22Benzodiazepines%22">Benzodiazepines</searchLink><br /><searchLink fieldCode="DE" term="%22Caffeine%22">Caffeine</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: We recognize that a paradigm shift of this magnitude takes time, as psychostimulants have been the mainstay of pharmacologic ADHD treatment for generations, but we are grateful to the editor for giving us this forum to share the experiences of our patients and their families from which we can learn. Comment on "Extended-Release Viloxazine Compared to Atomoxetine for Attention Deficit Hyperactivity Disorder" Following the 5-day washout period of atomoxetine, post-treatment scores were compared with baseline pretreatment scores to confirm that baseline scores were re-established prior to initiating viloxazine extended release (VER). [Extracted from the article]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of CNS Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=172948642
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s40263-023-01035-2
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 2
        StartPage: 939
    Subjects:
      – SubjectFull: Attention-deficit hyperactivity disorder
        Type: general
      – SubjectFull: Atomoxetine
        Type: general
      – SubjectFull: Benzodiazepines
        Type: general
      – SubjectFull: Caffeine
        Type: general
    Titles:
      – TitleFull: Authors' Reply to Pande et al. Comment on "Extended-Release Viloxazine Compared to Atomoxetine for Attention Deficit Hyperactivity Disorder".
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Price, Maxwell Z.
      – PersonEntity:
          Name:
            NameFull: Price, Richard L.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: Oct2023
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-print
              Value: 11727047
          Numbering:
            – Type: volume
              Value: 37
            – Type: issue
              Value: 10
          Titles:
            – TitleFull: CNS Drugs
              Type: main
ResultId 1